Real-world study of sintilimab combined with bevacizumab in patients with advanced hepatocellular carcinoma
Objective To explore the clinical efficacy and safety of sintilimab combined with bevacizumab in the treatment of advanced hepatocellular carcinoma(HCC).Methods Patients with advanced HCC diagnosed and treated in Xuzhou Cancer Hospital from January 2021 to January 2023 were retrospectively selected as study subjects.According to the treatment regimen,patients with advanced HCC were categorized into the sorafenib group(sorafenib treatment)and the monoclonal antibody group(sindilizumab+bevacizumab treatment).The primary study endpoints were progression-free survival(PFS)and overall survival(OS),and the secondary study endpoints were objective response rate(ORR)and disease control rate(DCR).The occurrence of adverse reactions was assessed according to the Common Terminology Criteria for Adverse Events(CTCAE 4.03).Results A total of 108 patients with advanced HCC were enrolled,36 in the sorafenib group and 72 in the monoclonal antibody group.The median PFS and OS were significantly higher in the monoclonal antibody group than in the sorafenib group(P<0.05).The ORR in the monoclonal antibody group was significantly higher than that in the sorafenib group(P<0.05),but the difference in DCR between the two groups was not statistically significant(P>0.05).Regarding adverse reactions,no fatal adverse reactions occurred in both groups,and the occurrence of adverse reactions was similar.Conclusion Compared with sorafenib,sindilizumab combined with bevacizumab resulted in better OS and PFS in advanced HCC with a favorable safety profile.
万方数据
维普
